Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
68 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Heterozygous familial hypercholesterolemia (heFH) - Pipeline Review, H1 2016', provides an overview of the Heterozygous familial hypercholesterolemia (heFH) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia (heFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Heterozygous familial hypercholesterolemia (heFH) and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Heterozygous familial hypercholesterolemia (heFH) - The report reviews pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Heterozygous familial hypercholesterolemia (heFH) therapeutics and enlists all their major and minor projects - The report assesses Heterozygous familial hypercholesterolemia (heFH) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Heterozygous familial hypercholesterolemia (heFH) Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Heterozygous familial hypercholesterolemia (heFH) - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Heterozygous familial hypercholesterolemia (heFH) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Heterozygous familial hypercholesterolemia (heFH) Overview 6 Therapeutics Development 7 Pipeline Products for Heterozygous familial hypercholesterolemia (heFH) - Overview 7 Heterozygous familial hypercholesterolemia (heFH) - Therapeutics under Development by Companies 8 Heterozygous familial hypercholesterolemia (heFH) - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Heterozygous familial hypercholesterolemia (heFH) - Products under Development by Companies 12 Heterozygous familial hypercholesterolemia (heFH) - Companies Involved in Therapeutics Development 13 Kastle Therapeutics LLC 13 Merck & Co., Inc. 14 Pfizer Inc. 15 Regeneron Pharmaceuticals, Inc. 16 Heterozygous familial hypercholesterolemia (heFH) - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Combination Products 18 Assessment by Target 19 Assessment by Mechanism of Action 21 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 (atorvastatin calcium + ezetimibe) - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 alirocumab - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 anacetrapib - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 bococizumab - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 MGL-3196 - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 MGL-3745 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 mipomersen sodium - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Heterozygous familial hypercholesterolemia (heFH) - Recent Pipeline Updates 42 Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects 57 Heterozygous familial hypercholesterolemia (heFH) - Product Development Milestones 58 Featured News & Press Releases 58 May 24, 2016: New Cholesterol Treatment Now Available for Canadians 58 Mar 23, 2016: Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Praluent (alirocumab) Study in Patients Undergoing LDL Apheresis Therapy 59 Mar 16, 2016: Regeneron and Sanofi Strongly Disagree with U.S. Jury Verdict in Ongoing Patent Litigation Regarding Praluent (alirocumab) Injection and Will Appeal 59 Feb 08, 2016: NICE issues draft guidance on alirocumab for lipid disorder 60 Dec 11, 2015: Regeneron and Sanofi Announce UnitedHealth Group Selects Praluent (alirocumab) Injection for Preferred Access 61 Nov 10, 2015: Regeneron and Sanofi Announce New Praluent Injection Analyses Presented at AHA Scientific Sessions 2015 62 Jul 24, 2015: Sanofi And Regeneron Announce FDA Approval Of Praluent (Alirocumab) Injection, The First Pcsk9 Inhibitor In The U.S., For The Treatment Of High LDL Cholesterol In Adult Patients 63 Mar 27, 2014: Sanofi and Regeneron To Present Alirocumab Clinical Data at the American College of Cardiology's 63rd Annual Scientific Session 65 Jan 14, 2014: Merck Voluntarily Recalls All Lots of LIPTRUZET in the United States From Wholesalers Due to Packaging Defects 66 Appendix 67 Methodology 67 Coverage 67 Secondary Research 67 Primary Research 67 Expert Panel Validation 67 Contact Us 67 Disclaimer 68
List of Tables
Number of Products under Development for Heterozygous familial hypercholesterolemia (heFH), H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Kastle Therapeutics LLC, H1 2016 13 Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Merck & Co., Inc., H1 2016 14 Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Pfizer Inc., H1 2016 15 Heterozygous familial hypercholesterolemia (heFH) - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 16 Assessment by Monotherapy Products, H1 2016 17 Assessment by Combination Products, H1 2016 18 Number of Products by Stage and Target, H1 2016 20 Number of Products by Stage and Mechanism of Action, H1 2016 22 Number of Products by Stage and Route of Administration, H1 2016 24 Number of Products by Stage and Molecule Type, H1 2016 26 Heterozygous familial hypercholesterolemia (heFH) Therapeutics - Recent Pipeline Updates, H1 2016 42 Heterozygous familial hypercholesterolemia (heFH) - Dormant Projects, H1 2016 57
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
